Gates Scholar’s contribution to diabetes research

  • June 28, 2010

A Gates Scholar is a joint first author of a new paper on the effects of diabetes, published in The Lancet.

The article, published in this week’s issue of The Lancet, shows that diabetes approximately doubles the risk of a wide range of blood vessel diseases, including heart attacks and different types of stroke.

The research is based on an analyisis of 700,000 people, each of whom was monitored for about a decade in 102 surveys conducted in 25 countries. The analysis was made by an international consortium led by Cambridge’s Dr Nadeem Sarwar and Professor John Danesh in the Cardiovascular Epidemiology Unit.

Rao Kondapally Seshasai is a joint first author of this research, which will also be presented at the American Diabetes Association’s 70th Scientific Sessions in Orlando, Florida.

Rao features also this week, alongside Gates Scholar Sebhat Erqou, in research published in the Archives of Internal Medicine on the use of statins. Contrary to previous reports based on more limited data, the research has found that short-term use of statins in patients without a history of heart attacks and strokes has only a borderline effect.

Latest News

The Gates Cambridge conversation: How can we improve people’s diet?

What works when it comes to reducing people’s intake of sugary drinks and junk food? Miriam Alvarado and Élisabeth Demers-Potvin both work on the evaluation of health prevention policies in […]

Learning to lead in Law

Ifeanyi Umunna has just been elected student body co-president at Harvard Law School for the 2026–2027 academic year. It’s a role that positions her as a central figure in student […]

Scholar publishes first book

A Gates Cambridge Scholar has published her first book, a hybrid work of lyric non-fiction, which deals with issues ranging from gendered violence and control and intergenerational silence to the politics […]

Gates Cambridge Originals: Luis Briseño-Roa

Luis Briseño-Roa’s career path – like many – has not been a linear one. He started in natural sciences and worked his way through biochemistry, neuroscience, biotech and finally pharma […]